The success stories with targeted therapies directed against PML::RARA and BCR::ABL in acute promyelocytic and chronic lymphocytic leukemia, respectively, but also the more recent clinical experience with inhibitors of kinase fusion proteins found in sarcoma, underscore this notion. The gene discussed is BCR; the disease is sarcoma.